An ail­ing As­traZeneca kicks two drugs out of the pipeline and an ex-drug part­ner’s share price is blast­ed

Last Oc­to­ber Synair­gen saw its shares clob­bered by the news that its Big Phar­ma part­ner As­traZeneca had scrapped a mid-stage study of their in­haled in­ter­fer­on be­ta ther­a­py AZD9412. The drug was de­signed to pre­vent crises for asth­mat­ics dur­ing cold sea­son, but a low num­ber of ex­ac­er­ba­tions was mak­ing it im­pos­si­ble to see whether or not it was hit­ting the pri­ma­ry end­point.

To­day, As­traZeneca $AZN used its quar­ter­ly roundup — fo­cused pri­mar­i­ly on rapid­ly falling rev­enue — to silent­ly toss the drug, cit­ing “strate­gic” rea­sons. And it al­so threw out AZD3412, a myeloper­ox­i­dase in­hibitor in mid-stage test­ing for Parkin­son’s that Glob­al­Da­ta had held out as a sig­nif­i­cant hope in that field.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA